India Watchdog Seeks Expanded Powers to Review Imported Drug Prices
This article was originally published in PharmAsia News
If NPPA investigates issues like landed costs of imported brands, it could bring about a more level playing field, industry sources say.
You may also be interested in...
MUMBAI - Several global pharmaceutical firms are heading for a collision with India's National Pharmaceutical Pricing Authority after the drug price regulator turned down their requests for an upward price revision of leading imported brands
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.